SCHEDULE: NewGenIvf Group Ltd: Insider Share Option Exercise

NewGenIvf Group Ltd insiders Wing Fung Alfred Siu and Hei Yue Tina Fong exercised share options for 113,702 Class B ordinary shares, increasing their beneficial ownership to 2.8%.

Summary

• Wing Fung Alfred Siu and Hei Yue Tina Fong, key insiders of NewGenIvf Group Ltd, have exercised share options for a total of 113,702 Class B ordinary shares.
• The exercise occurred on June 4, 2026, at an exercise price of US$0.0001 per share.
• This transaction increases their combined beneficial ownership of Class B ordinary shares to 113,771, representing 2.8% of the total Class B ordinary shares outstanding.
• The shares were allotted and issued on June 4, 2026, fully paid and non-assessable.
• The exercise of these options is part of an amendment to a previously filed Schedule 13D, originally filed on April 10, 2024.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. While insider option exercises can signal confidence, this filing primarily details a standard compensation-related transaction rather than a significant strategic shift or performance indicator.

Positives

• Insiders are exercising options, indicating confidence in the company's future.
• The exercise price was nominal (US$0.0001), suggesting favorable terms for the insiders.
• The transaction increases the beneficial ownership of key management personnel, potentially aligning their interests further with the company's success.

Negatives

• The filing is an amendment to a Schedule 13D, indicating a change in beneficial ownership that requires disclosure.
• The increase in insider ownership, while potentially positive, also concentrates control.

Risks

• The Reporting Persons hold shares to retain control of the Issuer, which could limit external influence or strategic changes.
• The Reporting Persons may acquire additional securities or dispose of holdings, which could impact share price and market dynamics.
• Future plans or proposals are not fully disclosed, leaving room for potential strategic shifts that could affect the company.

Future Outlook

The Reporting Persons expect to continuously evaluate their goals, objectives, and available business opportunities, and may change their plans or proposals in the future. They will consider various factors, including the company's business and prospects, market conditions, economic conditions, and regulatory matters when deciding whether to sell or retain their securities. They also reserve the right to acquire additional securities, dispose of holdings, or change their intentions.

Management Comments

• The Reporting Persons hold the Class B ordinary shares to retain control of the Issuer.
• The Reporting Persons expect to evaluate on a continuing basis their goals and objectives, other business opportunities available to them and may change their plans or proposals in the future.
• In determining from time to time whether to sell the securities reported as beneficially owned in this Amendment No.1 (and in what amounts) or to retain such securities, the Reporting Persons will take into consideration such factors as they deems relevant, including the business and prospects of the Company, anticipated future developments concerning the Company, existing and anticipated market conditions from time to time, general economic conditions, regulatory matters, and other opportunities available to the Reporting Persons.
• The Reporting Persons may, from time to time, transfer shares beneficially owned by them for tax, estate or other economic planning purposes.
• The Reporting Persons reserve the right to acquire additional securities of the Issuer in the open market, in privately negotiated transactions (which may be with the Issuer or with third parties) or otherwise, to dispose of all or a portion of their holdings of securities of the Issuer or to change his intention with respect to any or all of the matters referred to in this Item 4.

Industry Context

StockSavvy.ai notes that insider option exercises are common in the biotechnology and healthcare sectors, particularly for executives aiming to align their financial interests with the company's growth trajectory. This filing indicates active management participation in the company's equity structure.

Related Party Transactions

• The exercise of share options by Wing Fung Alfred Siu and Hei Yue Tina Fong, who are Chairman/CEO and Director/CMO respectively, and are spouses, constitutes a related party transaction.

Stakeholder Impact

• Shareholders: Increased insider ownership may lead to greater alignment of interests, but also concentrated control. The actual impact on share price is not immediately evident from this filing alone.
• Employees: The existence of the 2024 Share Incentive Plan, under which these options were exercised, suggests a mechanism for employee and executive compensation and retention.
• Management: The transaction directly benefits the named insiders through the acquisition of shares.

Next Steps

• Reporting Persons will continue to evaluate their investment strategy regarding NewGenIvf Group Ltd shares.
• Potential for future acquisition or disposition of securities by Reporting Persons.

Key Dates

Keywords

Schedule 13D, NewGenIvf Group Ltd, Wing Fung Alfred Siu, Hei Yue Tina Fong, Class B ordinary shares, Share options, Beneficial ownership, Insider transaction, SEC filing, Amendment